Regeneron Pharmaceuticals (REGN) Common Equity (2009 - 2026)

Regeneron Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $31.4 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 6.93% year-over-year to $31.4 billion in Q1 2026; TTM through Mar 2026 was $31.4 billion, a 6.93% increase from a year earlier, with the FY2025 full-year figure at $31.3 billion, up 6.48% from the prior year.
• Common Equity improved to $31.4 billion in Q1 2026 per REGN's latest filing, from $31.3 billion in the prior quarter.
• Across five years, Common Equity topped out at $31.4 billion in Q1 2026 and bottomed at $19.9 billion in Q1 2022.
• The 5-year median for Common Equity is $27.0 billion (2024), against an average of $26.5 billion.
• Across the five-year window, Common Equity surged 66.27% in 2022 and climbed 5.56% in 2025, its largest moves.
• Year by year, Common Equity stood at $22.7 billion in 2022, then advanced by 14.6% to $26.0 billion in 2023, then grew by 13.02% to $29.4 billion in 2024, then grew by 6.48% to $31.3 billion in 2025, then grew by 0.53% to $31.4 billion in 2026.
• Per Business Quant, the three latest REGN Common Equity figures stand at $31.4 billion (Q1 2026), $31.3 billion (Q4 2025), and $31.0 billion (Q3 2025).